We are familiar with the wide range of antihypertensive agents which are available to reduce blood pressure and if we go by the argument that reducing blood pressure reduces cardiovascular and stroke risk, treatment with any antihypertensive agent would seem good clinical practice. 1 Nevertheless, only a few classes of agents have been well tested in prospective longitudinal studies for mortality and morbidity, and if this is the evidence we simply rely on, surely we would be confining our antihypertensive drug prescriptions (until recently) to the thiazide and beta-blockers.
However, we commonly prescribe other antihypertensive agents because of their beneficial ancillary effects. One clear example of this are the angiotensin-converting enzyme (ACE) inhibitors which have beneficial effects in patients with concomitant heart failure due to systolic dysfunction, or diabetes. In respect of the latter, increasing evidence also shows that the ACE inhibitors would be beneficial in slowing the progression of diabetic nephropathy, diabetic retinopathy and possibly even diabetic neuropathy. Hence, the adage 'a pill for every ill' may well apply! The ACE inhibitors also appear to be the agents which are best in regressing left ventricular hypertrophy (LVH), as evident from metaanalyses by Cruckshank et al, 2 Dahlof et al 3 and Schmieder et al. 4 For example, in the meta-analysis by Schmieder et al 4 of randomised double-blind controlled studies, there was a decrease in left ventricular mass index which related to the degree of blood pressure and the duration of therapy; however, left ventricular mass was found to decrease by 13% by treatment with the ACE inhibitors, 9% with calcium channel blockers, 6% with beta-blockers and 7% with diuretics. There is also the recognition that ACE inhibitors have some beneficial effects in correcting the prothrombotic or hypercoagulable state in patients with hypertension, with particular The recent scares about the short-acting dihydropyridine calcium antagonists from pharmacosurveillance studies has been slightly (but perhaps not completely) refuted by large prospective randomised trials, such as the SYST-EUR and HOT studies which respectively used nitrendipine and felodipine. 7, 8 Calcium antagonists also have significant advantages in treating black patients with hypertension. 9 In terms of regression of LVH, however, they appear to be second to the ACE inhibitors, but the cynic may argue that with any antihypertensive agent, there would eventually be adequate reduction or regression of left ventricular hypertrophy or for that matter, any other type of organ damage with sufficient and long enough lowering of blood pressure.
Whilst these deliberations on the benefits of one agent over another continue, how does this apply to the real world? It is certainly well recognised that the trial setting may be artificial and that very often these patients get 'packages of care', which includes careful follow-up, and motivation by enthusiastic trial co-ordinators or research nurses. In this respect, any insight into how these different antihypertensive agents perform in a population sample would be of interest.
In this issue of the Journal of Human Hypertension, Bertil Andrén and colleagues 10 report a study of 584 70-year-old men with echocardiography, of whom 179 were treated for hypertension. They found no significant difference in left ventricular mass between the subjects who were treated with different antihypertensive agents after repeat echocardiography at 20 years follow-up. The patients were of a similar age but we are not given details regarding the duration of previously known hypertension or the degree of target organ damage at the start of the study. Nevertheless, the interesting point at follow-up is the similar left ventricular mass or blood pressure between the subjects treated with ACE inhibitors, calcium antagonists or beta-blockers as monotherapy.
There is little doubt that the study has significant limitations. When the patients were entered into the study, blood pressure was measured by many investigators. Within each class of drugs, agents used may have been fairly heterogeneous rather than simply the use of a single agent in a randomised trial setting. When the study was initiated in 1969-1970, no echocardiographic parameters were available and a further limitation, which could be considered as the reality of clinical practice, was that the general practitioners who managed the patients were free to treat their hypertensive patients as they felt appropriate. With age, left ventricular mass also increases, as does other co-morbidity, such as coronary artery disease or valvular disease. Diastolic Doppler parameters are also significantly altered by age, and in this respect, abnormalities in the diastolic function parameters do not come as a surprise. Their analysis of indices of diastolic function would therefore be open to a great many confounders.
Thus, this study has many weaknesses but nevertheless it highlights (or tries to) the 'usual' care or practice in the population setting. It is in keeping with the view that adequate treatment of blood pressure over a long enough period of time, leads to significant LVH regression which appears to be similar between the antihypertensive agents. One could postulate whether this translates into similar reductions in hard end-points such as heart attacks and strokes over a long enough period in the population setting, but studies of this length and duration are unlikely to be funded by grant-giving bodies or industry. Nevertheless, as a 'true' LVH regression study, the paper by Andrén and colleagues 10 fails miserably. They do not fulfil the criteria for an informative trial as suggested by Devereux and Dahlof 11 but one could argue that these criteria are more applicable to a study specifically examining LVH regression as an end-point.
The day may yet come when careful stringent follow-up of large numbers of patients taking various antihypertensive agents over a sufficiently long period of time (decades?) would ensure that with similar reduction of blood pressures, there may well be very little difference between one antihypertensive agent or the other in terms of LVH regression. Perhaps all antihypertensive drugs do regress LVH eventually, but the ACE inhibitors do it faster! Does LVH regression actually matter or is the final endpoint the only criterion? What about ancillary properties of the different antihypertensive agents? Do trials and meta-analysis reflect the reality of the 'real world' or 'usual care' in clinical practice? The many questions raised suggests that we are unlikely to hear the end on this matter.
